IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Decreased by Amalgamated Bank

Amalgamated Bank decreased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 17,580 shares of the company’s stock after selling 172 shares during the quarter. Amalgamated Bank’s holdings in IDEXX Laboratories were worth $8,882,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Nordea Investment Management AB increased its holdings in shares of IDEXX Laboratories by 15.5% in the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after acquiring an additional 1,839 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of IDEXX Laboratories during the first quarter worth $1,472,000. Commerce Bank lifted its position in shares of IDEXX Laboratories by 0.8% in the 1st quarter. Commerce Bank now owns 11,634 shares of the company’s stock worth $6,282,000 after buying an additional 91 shares during the last quarter. Rehmann Capital Advisory Group boosted its holdings in shares of IDEXX Laboratories by 3.1% in the 1st quarter. Rehmann Capital Advisory Group now owns 985 shares of the company’s stock valued at $532,000 after buying an additional 30 shares during the period. Finally, Csenge Advisory Group grew its position in shares of IDEXX Laboratories by 21.4% during the 1st quarter. Csenge Advisory Group now owns 943 shares of the company’s stock valued at $509,000 after buying an additional 166 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on IDXX. BTIG Research started coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Piper Sandler restated a “neutral” rating and set a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $415.98 on Wednesday. The stock has a fifty day moving average price of $476.04 and a two-hundred day moving average price of $486.32. The firm has a market cap of $34.24 billion, a P/E ratio of 40.11, a PEG ratio of 3.64 and a beta of 1.36. IDEXX Laboratories, Inc. has a 1 year low of $404.74 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm had revenue of $975.50 million for the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter last year, the business posted $2.53 EPS. IDEXX Laboratories’s revenue was up 6.6% on a year-over-year basis. Research analysts forecast that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.